Elefant Dov 4
4 · FEMASYS INC · Filed Mar 27, 2026
Research Summary
AI-generated summary of this filing
FEMASYS (FEMY) CFO Dov Elefant Receives Award of 34,122 Derivative Shares
What Happened
Dov Elefant, Chief Financial Officer of FEMASYS Inc. (FEMY), received an award of 34,122 derivative securities on March 19, 2026. The Form 4 reports these as derivative securities (Series D-1 warrants) rather than immediate shares; no cash price or immediate common-stock value was reported. The award was issued as part of a private placement in connection with an Omnibus Amendment and Consent Agreement.
Key Details
- Transaction date: March 19, 2026; Form 4 filed March 27, 2026 (filing appears late).
- Instrument: 34,122 Series D-1 warrant-based derivative securities (reported as an "A" — award/grant/acquisition of derivative securities).
- Exercise terms: initial exercise price $0.58 per common share (subject to adjustment for splits, dividends, recapitalizations, etc.).
- Limitations: Exercise subject to Nasdaq Capital Market limitations (may restrict exercising if certain Nasdaq rules apply).
- Consideration/Reason: Issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement dated March 19, 2026.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Timeliness: The Form 4 was filed 8 days after the transaction date; insiders are generally required to file within two business days, so this filing appears late (reduces short-term transparency).
Context
These are warrants/derivative awards, not immediate common shares. Elefant can acquire common stock only if and when these Series D-1 warrants are exercised (at the stated exercise price and subject to adjustments and Nasdaq limitations). Such awards can dilute existing shareholders if exercised but do not represent current stock sales or purchases by the insider.
Insider Transaction Report
- Award
Series D-1 Warrants
[F1][F3][F2]2026-03-19+34,122→ 34,122 totalExercise: $0.58From: 2026-03-19Exp: 2036-03-19→ Common stock, par value $0.001 per share (34,122 underlying)
Footnotes (3)
- [F1]Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
- [F2]The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
- [F3]The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.